Neopharm Injection

Adult dosage

Generally, 500 mL is administered by slow intravenous infusion. The infusion rate is based on a standard of no less than 180 minutes for 500 mL. When administered via central venous access, 500 mL should be mixed with carbohydrate solutions and continuously infused into the central vein over 24 hours. Dosage should be adjusted appropriately based on age, symptoms, and body weight.

This medication must be used according to a doctor's instructions. Using it arbitrarily without a doctor's prescription can pose health risks. This medication should not be administered to patients with severe renal impairment or hyperazotemia. Furthermore, it should also not be used in patients with amino acid metabolism disorders aside from liver failure. It is also safe to avoid administering this medication to patients with metabolic disorders causing nitrogen utilization issues, patients with cachetic heart disease, patients with pulmonary edema, or those with oliguria or anuria. Patients with hypernatremia, hyperchloremia, or alkalosis, as well as those in a state of excessive fluid supply and patients with a history of myocardial infarction should not use this medication. Cautious administration is required for patients with severe acidosis, congestive heart failure, or severe heart disease, as well as those with edema due to sodium retention and patients with reduced kidney function. This medication contains sodium bisulfite which may cause allergic reactions or asthma attacks in individuals with sulfite allergies or asthma. Rarely, hypersensitivity reactions such as skin rashes may occur during administration, and in such cases, usage should be immediately discontinued. Gastrointestinal symptoms such as nausea or vomiting, chest discomfort, palpitations, rapid pulse, and elevated blood pressure can occasionally appear. Rapid infusion in large volumes may lead to acidosis, so caution should be exercised. Severe side effects such as chills, fever, headaches, dyspnea, respiratory arrest, shock, bronchospasm, and urinary tract spasm may also occur rarely. Various metabolic complications such as metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, rebound hypoglycemia, elevated liver enzymes, vitamin deficiencies or excesses, electrolyte imbalances, or pediatric hyperammonemia may occur. Patients with impaired liver or kidney function may have elevated blood urea nitrogen (BUN) levels, necessitating caution. Patients with severe impaired liver function are at risk of serum amino acid imbalances, metabolic alkalosis, systemic azotemia, hyperammonemia, consciousness disturbances, or coma. When large doses are administered or in conjunction with electrolyte-containing solutions, careful monitoring of electrolyte balance is required. During overdose, metabolic alkalosis may occur, so preparations containing acidic ions should be used carefully. Administration to patients with kidney disease, lung disease, or severe heart disease should be done cautiously to avoid excessive fluid supply. Diabetic patients should frequently monitor their blood sugar levels while using this medication. Patients with hyponatremia and liver or kidney failure should adjust the dosage individually and carefully manage fluid balance and serum electrolyte levels. This medication can reduce the protein synthesis promoting effect of the specific antibiotic tetracycline when used in combination. Mixing vitamin B1 (thiamine) with this medication may reduce the effect of vitamin B1, so it is advisable not to use them together. The safety of this medication in pregnant women has not been sufficiently confirmed; thus it should only be administered cautiously when the therapeutic benefits outweigh the risks. For children, liver function may be immature, so maintaining lower concentrations for administration is preferable, and in infants, blood ammonia levels should be frequently monitored. Elderly patients often have diminished bodily functions, so the infusion rate should be slowed down and the dosage reduced for safe use. Since this medication contains electrolytes, careful attention to electrolyte balance is particularly important when large doses are administered or when used alongside other electrolyte solutions. Administer it slowly via IV injection, as rapid infusion can cause chills or vomiting and lead to significant amino acid loss via the kidneys. If stored in the refrigerator, it should be used within 24 hours, and it should not be used if the solution is cloudy or discolored. The preparation and administration of intravenous solutions should be done in an aseptic manner, paying close attention to the sterilization of syringes and equipment.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, pallor, dyspnea, respiratory arrest, shock, bronchoconstriction, severe edema accompanied by elevated blood pressure.

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• rapid pulse (tachycardia)
• elevated blood pressure
• metabolic acidosis
• hypophosphatemia
• alkalosis

This medication should be stored in a sealed container to prevent exposure to air, kept away from direct sunlight, and ideally stored at room temperature. This will help maintain the medication's efficacy for a longer period.

Appearance

An injection solution in a colorless, transparent glass vial containing a colorless to pale yellow, transparent liquid.

Package unit

250 milliliters/vial x 1